Benzinga | Apr 12, 2021 08:42AM EDT

BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting

* BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research (AACR) Annual Meeting 2021.

* The findings indicate disease control in advanced breast cancer patients, including stable disease (SD), partial responses (PR), or complete responses (CR).

* The Bria-IMT regimen with or without checkpoint inhibitors can induce an effective immune response and disease control in heavily pre-treated advanced breast cancer patients.

* Delayed-Type Hypersensitivity (DTH) to Bria-IMT analysis identified a group with significantly higher rates of disease control and progression-free survival (8 months) in both monotherapy and combination therapy studies suggesting a robust immune response is predictive of clinical benefit in these patients.

* The highest levels of disease control and progression-free survival were observed in patients who matched Bria-IMT at 2 or more HLA alleles in the monotherapy study but not in the combination therapy with Bria-OTS, off-the-shelf personalized immunotherapy for advanced breast cancer.

* Patients with Grade I/II tumors (median of 8 prior therapy regimens) were more likely to respond with the disease control (67%) and longer progression-free survival.

* The response was evident in the patients in the combination therapy study suggesting synergistic effects of checkpoint inhibitors combined with the Bria-IMT regimen.

* BriaCell is currently conducting a Phase 1/2a clinical trial of Bria-IMT in a Combination Study with immune checkpoint inhibitors.

* Price Action: BCTX shares are up 2.1% at $5.32 during the premarket session on the last check Monday.